GB9225859D0 - Novel treatment - Google Patents

Novel treatment

Info

Publication number
GB9225859D0
GB9225859D0 GB929225859A GB9225859A GB9225859D0 GB 9225859 D0 GB9225859 D0 GB 9225859D0 GB 929225859 A GB929225859 A GB 929225859A GB 9225859 A GB9225859 A GB 9225859A GB 9225859 D0 GB9225859 D0 GB 9225859D0
Authority
GB
United Kingdom
Prior art keywords
novel treatment
novel
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929225859A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GB929225859A priority Critical patent/GB9225859D0/en
Publication of GB9225859D0 publication Critical patent/GB9225859D0/en
Priority to EP94902047A priority patent/EP0674519A1/en
Priority to JP6513937A priority patent/JPH08504433A/ja
Priority to PCT/GB1993/002515 priority patent/WO1994013297A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB929225859A 1992-12-11 1992-12-11 Novel treatment Pending GB9225859D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB929225859A GB9225859D0 (en) 1992-12-11 1992-12-11 Novel treatment
EP94902047A EP0674519A1 (en) 1992-12-11 1993-12-08 Potassium channel activators and use thereof in therapy
JP6513937A JPH08504433A (ja) 1992-12-11 1993-12-08 カリウムチャネルアクチベーターおよびその治療における使用
PCT/GB1993/002515 WO1994013297A1 (en) 1992-12-11 1993-12-08 Potassium channel activators and use thereof in therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929225859A GB9225859D0 (en) 1992-12-11 1992-12-11 Novel treatment

Publications (1)

Publication Number Publication Date
GB9225859D0 true GB9225859D0 (en) 1993-02-03

Family

ID=10726440

Family Applications (1)

Application Number Title Priority Date Filing Date
GB929225859A Pending GB9225859D0 (en) 1992-12-11 1992-12-11 Novel treatment

Country Status (4)

Country Link
EP (1) EP0674519A1 (ja)
JP (1) JPH08504433A (ja)
GB (1) GB9225859D0 (ja)
WO (1) WO1994013297A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112143738B (zh) * 2020-09-30 2023-04-11 云南省烟草农业科学研究院 一种烟草受体蛋白基因及其克隆方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2639227A1 (fr) * 1988-11-23 1990-05-25 Sanofi Sa Utilisation de derives du chromane pour le traitement des etats depressifs
TW224941B (ja) * 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
IL101456A0 (en) * 1991-04-15 1992-12-30 Squibb & Sons Inc Indole and dihydroquinoline derivatives,and pharmaceutical compositions containing the same
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4115521A1 (de) * 1991-05-11 1992-11-12 Beiersdorf Ag Isoindolyl- und isochinolylsubstituierte benzopyran-derivate, zwischenprodukte, sowie verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
JPH08504433A (ja) 1996-05-14
EP0674519A1 (en) 1995-10-04
WO1994013297A1 (en) 1994-06-23

Similar Documents

Publication Publication Date Title
GB9215633D0 (en) Novel treatment
GB9208339D0 (en) Treatment composition
GB9127150D0 (en) Novel treatment
GB9226860D0 (en) Novel treatment
GB9211148D0 (en) Novel treatment
GB9203039D0 (en) Treatment
GB9225860D0 (en) Novel treatment
GB9226957D0 (en) Novel treatment
GB9226958D0 (en) Produktionsaktieselskab) novel treatment
GB9308802D0 (en) Treatment
AP9300527A0 (en) Novel treatment
GB9203637D0 (en) Novel treatment
GB9225859D0 (en) Novel treatment
GB9225862D0 (en) Novel treatment
GB9225957D0 (en) Novel treatment
GB9225959D0 (en) Novel treatment
GB9225961D0 (en) Novel treatment
GB9225963D0 (en) Novel treatment
GB9225964D0 (en) Novel treatment
GB9225956D0 (en) Novel treatment
GB9225948D0 (en) Novel treatment
GB9225881D0 (en) Novel treatment
GB9225863D0 (en) Novel treatment
AP9200456A0 (en) Novel treatment
GB9225861D0 (en) Novel treatment